Capital expenditure decreased 69.7%
Capital expenditure changed -69.7% from the comparable as-filed period. The change ranks at the 67th percentile of 6 prior comparable changes.
$1.9M→$569,0006 prior comparisons
GROSSPATTERN / DETERMINISTIC EVIDENCE / V3
Search securities →CVLT financial changes
Ranked by interpretable importance, issuer history, magnitude, and accounting profile. No directional recommendation.
Cash & equivalents increased 156.0%
Cash & equivalents changed +156.0% from the comparable as-filed period.
$363.2M→$929.8M2 prior comparisons
Free-cash-flow proxy increased 71.5%
Free-cash-flow proxy changed +71.5% from the comparable as-filed period. The change ranks at the 83th percentile of 6 prior comparable changes.
$29.8M→$51.1M6 prior comparisons
Operating cash flow increased 63.1%
Operating cash flow changed +63.1% from the comparable as-filed period. The change ranks at the 83th percentile of 6 prior comparable changes.
$31.7M→$51.7M6 prior comparisons
Capex / revenue moved 49 bp lower
Capex / revenue changed -49 basis points from the comparable as-filed period.
0.67%→0.18%2 prior comparisons
Stock-based compensation increased 16.9%
Stock-based compensation changed +16.9% from the comparable as-filed period.
$30.2M→$35.3M3 prior comparisons
Gross profit increased 11.0%
Gross profit changed +11.0% from the comparable as-filed period.
$231.2M→$256.5M3 prior comparisons
Net income decreased 10.0%
Net income changed -10.0% from the comparable as-filed period.
$23.5M→$21.1M3 prior comparisons
Revenue increased 11.4%
Revenue changed +11.4% from the comparable as-filed period.
$282.0M→$314.1M3 prior comparisons
Gross margin moved 33 bp lower
Gross margin changed -33 basis points from the comparable as-filed period.
81.99%→81.66%3 prior comparisons
Operating income increased 2.5%
Operating income changed +2.5% from the comparable as-filed period.
$25.1M→$25.7M3 prior comparisons
Operating margin moved 71 bp lower
Operating margin changed -71 basis points from the comparable as-filed period.
8.90%→8.19%3 prior comparisons
Research & development decreased 1.3%
Research & development changed -1.3% from the comparable as-filed period.
$40.1M→$39.5M3 prior comparisons
Method Importance combines metric-family relevance, magnitude, issuer-history unusualness, persistence, and financial-statement significance. It is analytical prioritization, not a legal materiality conclusion or investment signal.